ERBITUX®
(Cetuximab)

Documentation
Patented
Approved 2004
FDA Letter
FDA Label
Full Sequence
Brief Summary
Function Type: Antagonist
Target: EGFR
Indication Category: Cancer

Patented
Approved 2004
FDA Letter
FDA Label
Full Sequence
Function Type: Antagonist
Target: EGFR
Indication Category: Cancer